IMUX Q2 2020 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena

IMUXImmunic, Inc.

$138M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$12M

Net Income

-$11M

EPS (Diluted)

$-0.90

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$369,000

Balance Sheet

Total Assets

$87M

Total Liabilities

$8M

Stockholders' Equity

$79M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$12M	-$15M	+18.6%
Net Income	-$11M	-$15M	+22.1%